Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Celltrion (068270) Posts Consolidated Revenue of KRW 4.16T and Operating Profit of KRW 1.17T for the Fiscal Year; Receives ‘Unqualified’ Auditor’s Opinion

Posted on March 16, 2026July 14, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Posts Consolidated Revenue of KRW 4.16T and Operating Profit of KRW 1.17T for the Fiscal Year; Receives ‘Unqualified’ Auditor’s Opinion

Fact Source: Financial Supervisory Service DART / 2026-03-16

Disclosure Type: Submission of Audit Report

💡 3-Second Summary

Celltrion has officially submitted its audit report, recording consolidated revenue of approximately KRW 4.16 trillion and an operating profit of KRW 1.17 trillion, securing an “unqualified” audit opinion on both consolidated and separate financials from Samil PwC.

📊 1. [Summary of Key Disclosure Content and Major Figures]

  • External Auditor: Samil PwC (Samil PwC)
  • Date of Receiving Audit Report: March 16, 2026

[Consolidated Financial Highlights & Financial Position]

  • Revenue: KRW 4,162,495,108,881 (Approx. KRW 4.16T)
    • Increased by approximately 17.01% from the previous fiscal year (KRW 3,557,303,554,371).
  • Operating Profit: KRW 1,168,471,345,595 (Approx. KRW 1.17T)
    • Increased by approximately 137.49% from the previous fiscal year (KRW 492,015,534,847).
  • Net Income: KRW 1,031,483,789,240 (Approx. KRW 1.03T)
    • Increased by approximately 146.25% from the previous fiscal year (KRW 418,883,310,404).
  • Total Assets: KRW 22,334,900,189,800 (Approx. KRW 22.33T)
  • Total Liabilities: KRW 4,982,370,370,686 (Approx. KRW 4.98T)
  • Total Equity: KRW 17,352,529,819,114 (Approx. KRW 17.35T)
  • Share Capital: KRW 239,361,656,000 (Approx. KRW 239.4B)

[Separate/Individual Financial Highlights & Financial Position]

  • Revenue: KRW 2,928,637,506,047 (Approx. KRW 2.93T)
  • Operating Profit: KRW 918,952,338,732 (Approx. KRW 919.0B)
  • Net Income: KRW 847,542,675,067 (Approx. KRW 847.5B)
  • Total Assets: KRW 21,813,010,247,799 (Approx. KRW 21.81T)
  • Total Liabilities: KRW 4,403,286,860,823 (Approx. KRW 4.40T)
  • Total Equity: KRW 17,409,723,386,976 (Approx. KRW 17.41T)

[Audit Opinions & Supplementary Details]

  • Audit Opinion (Consolidated & Separate): Unqualified (No material uncertainties regarding going concern, and non-applicable (N/A) for non-unqualified opinions on the internal accounting control system).
  • Number of Consolidated Subsidiaries: 47 companies (An increase of 1 from the previous fiscal year).
  • Embezzlement/Malfeasance Mentioned: No.
  • Capital Impairment Rate: N/A

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

The submission of the audited financial statements is a critical event that provides verified performance metrics and risk factors validated by an external auditor, thereby solidifying market confidence. The “unqualified” opinion ensures the transparency of Celltrion’s accounting practices and reveals positive underlying fundamental trends.

On a consolidated basis, the prominent highlight is the dramatic expansion of operating profitability. Achieving an operating profit of approximately KRW 1.17T (a growth of over 137% year-on-year) and passing the KRW 1T mark in net income demonstrates the company’s strong earning power. Although liabilities increased along with assets, the company’s robust capital base (consolidated equity of approximately KRW 17.35T) implies that financial risks remain well-contained.

On the other hand, the parent-only (separate) figures showed a decline in separate revenue (KRW 2.93T) and operating profit (KRW 919.0B) compared to the prior year. This may reflect shifting transaction structures with overseas subsidiaries or localized business adjustments. Since the disclosure does not specify the concrete reasons for this separate earnings contraction, investors may analyze the discrepancy between consolidated and separate earnings to determine how much of the consolidated growth is driven by subsidiary performance. These audited figures remain subject to final confirmation at the upcoming general meeting of shareholders.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion has officially entered the KRW 4 trillion revenue era with a clean, unqualified report from Samil PwC. The consolidated operating profit surged more than twofold compared to the prior year, marking a stellar recovery in profitability that will serve as a firm foundation for future fundamental enhancements. However, discerning the difference in margin dynamics between the booming consolidated results and the flat parent-only performance will be crucial for analytical depth. With accounting integrity cleared, watching how these robust cash flows feed into the actual shareholder return policies after the annual meeting is a sensible next step.

📢 Disclaimer and Source Information

Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s electronic disclosure system (DART).

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Jeju Semiconductor (080220) Issues $10B KRW Private Bond with Warrants (BW) to Solidify Global Partnership and Secure Raw Materials
Next Post: [Disclosure] Wonik IPS (240810) Submits Audit Report with ‘Unqualified’ Opinion; FY2025 Operating Profit Surges 594% to KRW 73.8B

Related Posts

[Disclosure] SK Hynix (000660) Decides to Acquire Next-Gen EUV Equipment Worth Approximately 12 Trillion KRW Semiconductors
[Disclosure] Alteogen (196170) Designated as Short-Selling Overheated Stock; Short-Selling Banned on May 15 Disclosures
[Disclosure] Samsung Biologics (207940) Extends CMO Contract Period with Roche: KRW 605.3B Deal Prolonged to End of 2025 Disclosures
[Disclosure] Samsung Biologics (207940) Extends Confidentiality Period on Contract Timeline to 2026 for CMO Agreement with Ichnos Sciences Disclosures
[Disclosure] Samsung Biologics Announces Adjustments to Stock Futures & Options Final Trading Day Due to Corporate Split (207940) Disclosures
[Disclosure] SK Hynix (000660) Updates AGM Agenda: Inclusion of Treasury Stock Disposal Plan and Board Restructuring Semiconductors

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P44’ (Darzalex Biosimilar) in EuropeJuly 14, 2026
  • [Disclosure] Hanmi Semiconductor (042700) Reports Q2 2026 Operating Profit of KRW 130.3B… A Explosive 1,441.4% QoQ SurgeJuly 14, 2026
  • [Disclosure] SK Square (402340) Discloses Subsidiary SK Hynix’s Successful ADR Listing on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] SK Hynix (000660) Completes Listing of ADRs (American Depositary Receipts) on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] Samsung Electronics (005930) to Dispose of KRW 322.8B Worth of Treasury Shares for Executive BonusesJuly 13, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme